Format

Send to

Choose Destination
J Hepatol. 2017 Dec;67(6):1350-1352. doi: 10.1016/j.jhep.2017.07.019. Epub 2017 Aug 5.

Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries".

Author information

1
University Hospital, Frankfurt am Main, Germany. Electronic address: zeuzem@em.uni-frankfurt.de.
2
Gilead Sciences, Inc., Foster City, CA, United States.
PMID:
28789882
DOI:
10.1016/j.jhep.2017.07.019

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center